<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2020.101002</article-id><article-id pub-id-type="publisher-id">WJCR-33347</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20200100000_70739819.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  miRNA在多发性骨髓瘤中的研究进展
  Research Progress of miRNA in Multiple Myeloma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>琳琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>洪岭</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>华北理工大学研究生学院，河北 唐山；河北省人民医院血液科，河北 石家庄</addr-line></aff><aff id="aff3"><addr-line>河北省人民医院血液科，河北 石家庄</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>01</issue><fpage>10</fpage><lpage>15</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    微小RNA(miRNA)是内源性非编码小RNA，参与转录后基因表达调控，随着对miRNA认识的不断增加，发现其通过影响骨髓瘤细胞的生长、增殖、克隆形成、凋亡，参与了多发性骨髓瘤的发生发展，本文总结了当前关于miRNA在多发性骨髓瘤发病机制、诊断价值、治疗及预后中的相关研究进展。
    MicroRNA (miRNA) is endogenous non-coding small RNA involved in post-transcriptional gene expression regulation. With the increasing recognition of miRNA, it has been found to affect the development and progression of multiple myeloma by affecting the growth, proliferation, clonal formation and apoptosis of MM cell. This review summarizes current research advances about roles of miRNA in the biological mechanism of multiple myeloma, including pathogenesis, diagnostic value, treatment, and prognosis. 
  
 
</p></abstract><kwd-group><kwd>微小RNAs，多发性骨髓瘤, MicoRNAs</kwd><kwd> Multiple Myeloma</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>miRNA在多发性骨髓瘤中的研究进展<sup> </sup></title><p>刘琳琳<sup>1,2</sup>，郝洪岭<sup>2*</sup></p><p><sup>1</sup>华北理工大学研究生学院，河北 唐山</p><p><sup>2</sup>河北省人民医院血液科，河北 石家庄</p><p><img src="//html.hanspub.org/file/2-2150182x1_hanspub.png" /></p><p>收稿日期：2019年11月19日；录用日期：2019年12月2日；发布日期：2019年12月9日</p><disp-formula id="hanspub.33347-formula48"><graphic xlink:href="//html.hanspub.org/file/2-2150182x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>微小RNA(miRNA)是内源性非编码小RNA，参与转录后基因表达调控，随着对miRNA认识的不断增加，发现其通过影响骨髓瘤细胞的生长、增殖、克隆形成、凋亡，参与了多发性骨髓瘤的发生发展，本文总结了当前关于miRNA在多发性骨髓瘤发病机制、诊断价值、治疗及预后中的相关研究进展。</p><p>关键词 :微小RNAs，多发性骨髓瘤</p><disp-formula id="hanspub.33347-formula49"><graphic xlink:href="//html.hanspub.org/file/2-2150182x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2150182x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2150182x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>多发性骨髓瘤(multiple myeloma, MM)是一种异质性很强的浆细胞来源的恶性肿瘤，约占血液系统恶性肿瘤的10%。越来越多的研究表明，微小RNA (microRNA, miRNA)在MM的发生、发展等过程中发挥了关键的作用。miRNA是长度为18~24个单链非编码RNA，通过与靶基因mRNA非翻译区(3’UTR)特异性结合，直接调控转录后基因表达。本文就miRNA在MM中的异常表达及意义作一综述。</p></sec><sec id="s4"><title>2. miRNA与MM发病机制</title><p>大量研究表明，MM的发病机制与miRNA异常表达有关。Qi等 [<xref ref-type="bibr" rid="hanspub.33347-ref1">1</xref>] 对87例MM患者进行研究，观察到miR-335表达下降。基于miRNA表达减少可能与启动子高甲基化有关这一观点，Qi等人利用生物信息学软件分析miR-335的启动子，定位出许多容易发生甲基化修饰的CpG岛，检测U266和正常人骨髓基质细胞HS-5细胞的甲基化水平，发现U266细胞中甲基化水平(78.8%)显着高于HS-5细胞(57.5%)。进一步检测MM患者和健康对照的甲基化状态，结果示87例MM患者中11例MM患者的miR-335启动子完全甲基化，76例患者miR-335启动子部分甲基化，而健康对照组甲基化miR-335的比例仅为50%。用5-氮杂胞苷处理MM细胞株，观察到miR-335的表达水平显着增加。在MM细胞株中转染miRNA-335模拟物和miRNA-335抑制剂，发现转染miRNA-335模拟物的细胞株迁移能力显著下降，但并未影响细胞的增殖和凋亡，通过生物信息学方法和荧光素酶报告基因法证实miR-335的靶基因是IGF-1R。简言之，miR-335在MM中通过靶向IGF-1R抑制细胞转移，但启动子高甲基化抑制了miR-335表达。</p><p>Long等 [<xref ref-type="bibr" rid="hanspub.33347-ref2">2</xref>] 对27例MM患者和11例健康者的骨髓穿刺液进行研究，发现MM患者的miR-765显著升高。将miR-765抑制剂转染到MM细胞株，在不同时间点进行细胞计数，发现miR-765的下调在48小时和72小时显著抑制了U266和RPMI-8226细胞株增殖，通过流式细胞术分析发现转染miR-765抑制剂的U266和RPMI-8226细胞的凋亡率明显升高，表明miR-765可能在MM的发生发展中起致癌作用。通过生物信息学和荧光素酶试验证实miR-765的直接靶基因是SOX6，该基因参与多种类型人类肿瘤的发生发展。</p><p>Zhang等 [<xref ref-type="bibr" rid="hanspub.33347-ref3">3</xref>] 对30例MM患者和10例健康人进行研究，发现MM患者miR-15a和miR-16的表达是明显下降。将miR-15a和miR-16转染MM细胞株，通过RT-qPCR和蛋白质印迹技术发现CABIN1 mRNA和蛋白质水平均减低。CABIN1的过表达可抑制p53在靶基因的转录活性，包括CDKN1A [<xref ref-type="bibr" rid="hanspub.33347-ref4">4</xref>]。进一步将miR-15、miR-16和CABIN1 siRNA分别转染MM细胞株，应用蛋白印迹技术发现miR-15、miR-16或CABIN1 siRNA均降低了MM细胞株CABIN1和p53下游基因CDKN1A的表达，表明miR-15a和miR-16的下调促进CABIN1表达，参与了MM的发生发展。</p><p>Lu等 [<xref ref-type="bibr" rid="hanspub.33347-ref5">5</xref>] 观察到MM患者miR-320a的表达下降。通过研究miR-320a在MM中的生物学功能，结果示miR-320a过表达可显著抑制MM细胞生存和克隆形成，诱导MM细胞凋亡。蛋白印迹分析发现在MM细胞株中过表达miR-320a可显著提高细胞凋亡蛋白(活化凋亡蛋白多聚ADP-核糖聚合酶、活化半胱氨酸蛋白酶蛋白-3)的水平，且发现miR-320a的靶基因是PBX3，提示miR-320a在MM中是一种抑癌基因。</p><p>miR-17-92簇是编码6个miRNA (miR-17、miR-18a、miR-19a、miR-19b、miR-20a和miR-92)的多顺反子基因，它被认为在许多癌症的发挥了关键作用。Wang等 [<xref ref-type="bibr" rid="hanspub.33347-ref6">6</xref>] 发现MM患者miR-19b明显升高。将miR-19b模拟物转染MM肿瘤干细胞，发现miR-19b模拟物可促进MM肿瘤干细胞克隆、增殖，且通过调节活化的细胞凋亡蛋白酶3的表达抑制MM肿瘤干细胞凋亡，并且证实了miR-19b的靶基因是TSC1。通过定量逆转录PCR和蛋白印迹分析发现MM患者的TSC1 mRNA水平明显低于健康受试者，而p-S6K蛋白水平明显高于健康受试者，说明miR-19b通过调控TSC1和p-S6K的表达诱导MM的肿瘤形成。Zhang等 [<xref ref-type="bibr" rid="hanspub.33347-ref7">7</xref>] 对MM细胞株和正常骨髓细胞进行了研究，发现MiR-19a在MM细胞株中明显升高。将miR-19a模拟物/抑制剂转染MM细胞株，结果示miR-19a增强MM细胞的增殖及侵袭性，降低了药物诱导凋亡的敏感性。深入研究发现miR-19a通过调节PTEN/AKT/pAKT途径调节MM细胞凋亡和耐药性，说明miR-19a在MM的发生发展中扮演了致癌基因的作用。Yuan等 [<xref ref-type="bibr" rid="hanspub.33347-ref8">8</xref>] 检测了新诊断的MM (newly diagnosed MM, NDMM)患者、复发难治性MM (relapsed refractory MM, RRMM)患者、完全缓解(complete remission, CR)患者和健康受试者血清中miR-19b/20a的表达水平，结果显示与健康受试者相比，NDMM和RRMM患者miR-19b/20a的表达明显升高；与NDMM患者相比，CR时miR-19b/20a的表达明显降低。进一步研究发现NDMM患者骨髓活检标本CD138+细胞miR-19b/20a表达明显高于健康对照组。通过细胞转染技术，发现miR-19b/20a的过表达增强了U266细胞株的增殖、迁移和抗凋亡能力。并且证实了miR-19b和miR-20a直接靶向PTEN基因，说明miR-19b/20a在MM中是通过抑制PTEN发挥致癌作用。</p></sec><sec id="s5"><title>3. miRNA与MM相关基础研究</title><p>表观遗传学异常在血液系统恶性肿瘤中很常见，组蛋白去乙酰化酶(HDACs)是调节组蛋白和非组蛋白乙酰化状态的关键酶，早期研究表明HDAC调控参与癌症发生发展基因的表达。HDAC的过度表达促进癌细胞的侵袭，迁移，血管生成，降低细胞的粘附和凋亡。Nicola Amodio等 [<xref ref-type="bibr" rid="hanspub.33347-ref9">9</xref>] 研究了miR-29b在抑制异常HDAC活性的作用，以及miR-29b的表达是否可以通过乙酰化来控制，证实miR-29b可抑制HDAC4表达，且HDAC4抑制引起miR-29a/b-1启动子区域内组蛋白H4的高乙酰化，导致miR-29b表达增加。miR-29b和HDAC4之间存在负反馈调节，在小鼠MM移植模型中，观察HDAC4抑制剂的疗效，结果显示各组疗效依次为HDAC4抑制剂联合miR-29b模拟物组 &gt; miR-29b模拟物组 &gt; HDAC4抑制剂 &gt; 阴性对照组。</p><p>Wu等 [<xref ref-type="bibr" rid="hanspub.33347-ref10">10</xref>] 发现MiR-34a过表达抑制MM细胞增殖、克隆形成，且促进MM细胞凋亡。在非肥胖糖尿病合并重度免疫缺陷的小鼠移植模型中，发现MM肿瘤干细胞中miR-34a的过度表达降低了小鼠的致瘤性和溶骨性病变，并且证实miR-34a的直接靶基因是TGIF2。</p><p>Nicola Amodio等 [<xref ref-type="bibr" rid="hanspub.33347-ref11">11</xref>] 发现miR-155在MM细胞中下调，将miR-155模拟物转染MM细胞株，结果示miR-155通过增加细胞周期抑制剂p21的表达抑制MM细胞生长，通过增加天冬氨酸蛋白水解酶-3 (caspase-3)和天冬氨酸蛋白水解酶-7 (caspase-7)的裂解诱导MM细胞凋亡，进一步研究发现miR-155过表达可以增强硼替佐米抑制细胞增殖和诱导细胞凋亡的作用。进一步体内实验，将携带miR-155的慢病毒转导OPM2细胞株移植到小鼠体内，结果示miR-155可以增强硼替佐米抑制MM肿瘤的生长的作用。</p><p>Yuan等 [<xref ref-type="bibr" rid="hanspub.33347-ref12">12</xref>] 发现MM耐药细胞株8266-BR和H929-BR的耐药相关蛋白MDR1表达明显升高。进一步研究发现在耐药细胞株8266-BR和H929-BR中miR-520g和miR-520h表达显著下降。miR-520g和miR-520h均位于人类19号染色体上，通过结合位点的在线数据库及荧光素酶报告实验证实miR-520g和miR-520h靶向APE1。将miR-520g + miR-520h的慢病毒载体转染RPMI-8226R5 MM细胞，皮下注射到小鼠体内，结果示miR-520g + miR-520h的慢病毒载体转染RPMI-8226R5 MM细胞组生长较阴性对照组慢，说明miR-520g和miR-520h的联合过表达抑制了小鼠模型中硼替佐米耐药MM肿瘤的生长，为治疗硼替佐米耐药的MM提供了新的靶点。</p><p>Yuan等 [<xref ref-type="bibr" rid="hanspub.33347-ref8">8</xref>] 将miR-20a慢病毒载体和miR-20a抑制剂慢病毒载体分别稳定转染U266细胞，并注射到小鼠体内，发现miR-20a可以在小鼠体内促进肿瘤生长，miR-20a抑制剂可以抑制小鼠体内的肿瘤形成。进一步研究发现与接受空载体U266细胞的小鼠相比，注射慢病毒-miR-20a抑制剂转染的U266细胞的小鼠的寿命显著延长，提示miR-20a抑制剂具有抗肿瘤作用。肿瘤切除标本的免疫组织化学分析显示，与接受空载体U266细胞的小鼠相比，注射慢病毒-miR-20a抑制剂转染的U266细胞的小鼠的肿瘤组织Ki67表达更低，Bcl-2表达更高。</p><p>Xu等 [<xref ref-type="bibr" rid="hanspub.33347-ref13">13</xref>] 将MM的LP1细胞株皮下注射到雌性裸鼠体内，当肿瘤可触及时，将小鼠随机分为两组，分别将miR-26a模拟物或阴性对照注入到肿瘤，试验结束后将肿瘤组织切除，结果显示相比阴性对照，注射miR-26a模拟物的肿瘤重量轻，提示miRNA-26a可抑制肿瘤生长。</p></sec><sec id="s6"><title>4. miRNA在MM中的诊断及预后价值</title><sec id="s6_1"><title>4.1. miRNA在MM中的诊断价值</title><p>有研究表明硫酸软骨素蛋白聚糖在MM的诊断中具有较高的敏感性和特异性，且发现其表达受miRNA的调节。Nidhi Gupta等 [<xref ref-type="bibr" rid="hanspub.33347-ref14">14</xref>] 研究了miRNA (miR-143, miR-144, miR-199, miR-203)和硫酸软骨素蛋白聚糖在MM中的表达，结果示随着疾病的进展，硫酸软骨素蛋白聚糖水平越高，则miRNA水平越低，通过ROC曲线，发现miR-203对MM的诊断具有较高的敏感性和特异性。</p><p>Jiang等 [<xref ref-type="bibr" rid="hanspub.33347-ref15">15</xref>] 对35例MM患者进行研究，发现MM患者血清miR-125b-5p显著升高，miR-125b-5p能够准确区分MM患者和健康受试者，通过ROC曲线分析，结果显示miR-125b-5p的曲线下面积为0.954，敏感性为86%，特异性为96% (95%置信区间：0.901~1.006；P &lt; 0.001)，证明miR-125b-5p在MM中具有较高的诊断意义。</p><p>Qi等 [<xref ref-type="bibr" rid="hanspub.33347-ref1">1</xref>] 利用ROC曲线探索miR-335的诊断作用，曲线下面积为0.7786 (95%CI：0.7010~0.8562)，临界值为34.86时，敏感性为60.92%，特异性为89.13%，对部分患者进行随访，发现接受化疗的18例MM患者，化疗后miR-335表达升高，25例MM患者复发后，miR-335的表达降低。因此miR-335可用于MM的诊断和预测疾病进展。</p></sec><sec id="s6_2"><title>4.2. miRNA在MM中的预后价值</title><p>Che等 [<xref ref-type="bibr" rid="hanspub.33347-ref16">16</xref>] 发现MM患者的miR-27明显升高，分析显示高表达miR-27的患者具有更高的风险分层(IMWG及IPSS)，提示miR-27表达越高则预后越差。</p><p>Ren等 [<xref ref-type="bibr" rid="hanspub.33347-ref17">17</xref>] 发现MM患者miRNA-720和miRNA-1246表达明显增加，研究表明化疗后miRNA-720和miRNA-1246水平下降的患者无进展生存为17.84个月，而升高的患者无进展生存为12.40个月，提示miRNA-720和miRNA-1246水平越高，患者预后越差。治疗前后动态监测对临床预后有指导意义。</p><p>Hao等 [<xref ref-type="bibr" rid="hanspub.33347-ref18">18</xref>] 观察到MM患者血清中miR-214和miR-135b明显增高。收集104例新诊断的MM患者的全身X显扫描资料，以X线结果作为有无溶骨性损害的依据，结果示相比没有溶骨性病变的MM，有溶骨性病变患者血清中的miR-214和miR-135b水平更高。进一步研究发现miR-214越高，患者的无进展生存期和总生存期越短。</p></sec></sec><sec id="s7"><title>5. 结语</title><p>自1993年miRNAs被发现以来，人们对其在多发性骨髓瘤发病和进展中作用的认识逐渐提高，但目前的研究报道大多样本量偏小，尚需更多的研究进一步证明miRNAs在MM的发病机制、诊断、治疗及预后中的作用。</p></sec><sec id="s8"><title>文章引用</title><p>刘琳琳,郝洪岭. miRNA在多发性骨髓瘤中的研究进展Research Progress of miRNA in Multiple Myeloma[J]. 世界肿瘤研究, 2020, 10(01): 10-15. https://doi.org/10.12677/WJCR.2020.101002</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.33347-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Qi, J., Shi, L.Y., Wu, Y., et al. (2019) Epigenetic Silencing of miR-335 Induces Migration by Targeting Insulin-Like Growth Factor-1 Receptor in Multiple Myeloma. Leukemia &amp; Lymphoma, 13, 1-11.  
https://doi.org/10.1080/10428194.2019.1627534</mixed-citation></ref><ref id="hanspub.33347-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Long, S., Long, S., He, H., et al. (2019) MicroRNA-765 Is Pregulated in Multiple Myeloma and Serves an Oncogenic Role by Directly Targeting SOX6. Experimental and Therapeutic Medicine, 17, 4741-4747.  
https://doi.org/10.3892/etm.2019.7473</mixed-citation></ref><ref id="hanspub.33347-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, L., Zhou, L., Shi, M., et al. (2018) Downregulation of miRNA-15a and miRNA-16 Promote Tumor Proliferation in Multiple Myeloma by Increasing CABIN1 Expression. Oncology Letters, 15, 1287-1296.  
https://doi.org/10.3892/ol.2017.7424</mixed-citation></ref><ref id="hanspub.33347-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jang, H., Choi, S.Y., Cho, E.J., et al. (2009) Cabin1 Restrains p53 Activity on Chromatin. Nature Structural &amp; Molecular Biology, 16, 910-915. https://doi.org/10.1038/nsmb.1657</mixed-citation></ref><ref id="hanspub.33347-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Y., Wu, D., Wang, J., et al. (2016) miR-320a Regulates Cell Proliferation and Apoptosis in Multiple Myeloma by Targeting Pre-B-Cell Leukemia Transcription Factor 3. Biochemical and Biophysical Research Communications, 473, 1315-1320. https://doi.org/10.1016/j.bbrc.2016.04.069</mixed-citation></ref><ref id="hanspub.33347-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, N., Liang, X., Yu, W., et al. (2018) Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma. Cellular Physiology and Biochemistry, 50, 1804-1814. https://doi.org/10.1159/000494821</mixed-citation></ref><ref id="hanspub.33347-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Chen, Y., Zhao, P., et al. (2017) MicroRNA-19a Functions as an Oncogene by Regulating PTEN/AKT/pAKT Pathway in Myeloma. Leukemia &amp; Lymphoma, 58, 932-940. https://doi.org/10.1080/10428194.2016.1213827</mixed-citation></ref><ref id="hanspub.33347-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, J., Su, Z., Gu, W., et al. (2019) MiR-19b and miR-20a Suppress Apoptosis, Promote Proliferation and Induce Tumorigenicity of Multiple Myeloma Cells by Targeting PTEN. Cancer Biomark, 24, 279-289.  
https://doi.org/10.3233/CBM-182182</mixed-citation></ref><ref id="hanspub.33347-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Amodio, N., Stamato, M.A., Gullà, A.M., et al. (2016) Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics, 15, 1364-1375.  
https://doi.org/10.1158/1535-7163.MCT-15-0985-T</mixed-citation></ref><ref id="hanspub.33347-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wu, S., He, X., Li, M., et al. (2016) MiRNA-34a Overexpression Inhibits Multiple Myeloma Cancer Stem Cell Growth in Mice by Suppressing TGIF2. American Journal of Translational Research, 8, 5433-5443.</mixed-citation></ref><ref id="hanspub.33347-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Amodio, N., Gallo Cantafio, M.E., Botta, C., et al. (2019) Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers (Basel), 11, 236.  
https://doi.org/10.3390/cancers11020236</mixed-citation></ref><ref id="hanspub.33347-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yuan, X., Ma, R., Yang, S., et al. (2019) miR-520g and miR-520h Overcome Bortezomib Resistance in Multiple Myeloma via Suppressing APE1. Cell Cycle, 18, 1660-1669. https://doi.org/10.1080/15384101.2019.1632138</mixed-citation></ref><ref id="hanspub.33347-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Y.Y., Song, Y.Q., Huang, Z.M., et al. (2019) MicroRNA-26a Inhibits Multiple Myeloma Cell Growth by Suppressing Cyclin-Dependent Kinase 6 Expression. The Kaohsiung Journal of Medical Sciences, 35, 277-283.  
https://doi.org/10.1002/kjm2.12057</mixed-citation></ref><ref id="hanspub.33347-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, N., Kumar, R., Seth, T., et al. (2019) Clinical Significance of Circulatory microRNA-203 in Serum as Novel Potential Diagnostic Marker for Multiple Myeloma. Journal of Cancer Research and Clinical Oncology, 145, 1601-1611.  
https://doi.org/10.1007/s00432-019-02896-1</mixed-citation></ref><ref id="hanspub.33347-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Y., Luan, Y., Chang, H., et al. (2018) The Diagnostic and Prognostic Value of Plasma microRNA-125b-5p in Patients with Multiple Myeloma. Oncology Letters, 16, 4001-4007. https://doi.org/10.3892/ol.2018.9128</mixed-citation></ref><ref id="hanspub.33347-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Che, F., Wan, C., Dai, J., et al. (2019) Increased Expression of miR-27 Predicts Poor Prognosis and Promotes Tumorigenesis in Human Multiple Myeloma. Bioscience Reports, 39, BSR20182502.  
https://doi.org/10.1042/BSR20182502</mixed-citation></ref><ref id="hanspub.33347-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ren, Y., Li, X., Wang, W., et al. (2017) Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 17, 415-423.  
https://doi.org/10.1016/j.clml.2017.05.010</mixed-citation></ref><ref id="hanspub.33347-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hao, M., Zang, M., Zhao, L., et al. (2016) Serum High Expression of miR-214 and miR-135b as Novel Predictor for Myeloma Bone Disease Development and Prognosis. Oncotarget, 7, 19589-19600.  
https://doi.org/10.18632/oncotarget.7319</mixed-citation></ref></ref-list></back></article>